Hennion & Walsh Asset Management Inc. Grows Holdings in Vera Therapeutics, Inc. $VERA

Hennion & Walsh Asset Management Inc. grew its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 70.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,286 shares of the company’s stock after purchasing an additional 13,289 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.05% of Vera Therapeutics worth $938,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Perigon Wealth Management LLC lifted its holdings in Vera Therapeutics by 23.9% during the 3rd quarter. Perigon Wealth Management LLC now owns 12,898 shares of the company’s stock valued at $375,000 after buying an additional 2,492 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in shares of Vera Therapeutics during the third quarter worth approximately $13,097,000. Swedbank AB bought a new stake in shares of Vera Therapeutics during the third quarter valued at approximately $1,453,000. Squarepoint Ops LLC boosted its holdings in shares of Vera Therapeutics by 232.0% in the second quarter. Squarepoint Ops LLC now owns 57,519 shares of the company’s stock valued at $1,355,000 after purchasing an additional 40,196 shares during the period. Finally, Hudson Bay Capital Management LP bought a new position in Vera Therapeutics in the second quarter worth approximately $7,044,000. 99.21% of the stock is currently owned by institutional investors.

Insider Activity at Vera Therapeutics

In other news, Director Patrick G. Enright purchased 5,882 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the acquisition, the director owned 5,882 shares of the company’s stock, valued at $249,985. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the sale, the senior vice president owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their position. The disclosure for this sale is available in the SEC filing. 16.30% of the stock is owned by company insiders.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $48.71 on Friday. The company has a market capitalization of $3.11 billion, a PE ratio of -12.21 and a beta of 1.16. The company has a 50-day simple moving average of $40.18 and a two-hundred day simple moving average of $30.14. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter last year, the company posted ($0.85) EPS. Research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VERA has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their target price on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Evercore ISI lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Friday, November 28th. Bank of America raised their target price on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $74.83.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.